These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 17476141

  • 21. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
    Cabrespine A, Guy L, Khenifar E, Curé H, Fleury J, Penault-Llorca F, Kwiatkowski F, Barthomeuf C, Chollet P, Bay JO.
    Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
    [Abstract] [Full Text] [Related]

  • 22. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W, Nakabayashi M, Regan MM, Oh WK.
    Cancer; 2007 Dec 15; 110(12):2709-15. PubMed ID: 17960608
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer.
    Pintér O, Molnár J, Tóth C, Szabó Z, Lipták J, Fél P, Papp G, Hollman E, Hazay L, Streit B, Kisbenedek L, Fehér M, Kocsis I, Pajor L.
    In Vivo; 2005 Dec 15; 19(4):787-92. PubMed ID: 15999550
    [Abstract] [Full Text] [Related]

  • 25. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S.
    Eur Urol; 2007 Oct 15; 52(4):1020-7. PubMed ID: 17360103
    [Abstract] [Full Text] [Related]

  • 26. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
    Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM.
    BJU Int; 2009 Jun 15; 103(12):1641-6. PubMed ID: 19210673
    [Abstract] [Full Text] [Related]

  • 27. [Treatment of hormone-refractory prostate cancer with estramustine phosphate].
    Morote J, López-Pacios MA, Ahmad A, Vila J, de Torres JA.
    Actas Urol Esp; 1991 Jun 15; 15(5):421-4. PubMed ID: 1725472
    [Abstract] [Full Text] [Related]

  • 28. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E, Banu A, Medioni J, Levy E, Thiounn N, Mejean A, Andrieu JM, Oudard S.
    Prostate; 2007 Oct 01; 67(14):1543-9. PubMed ID: 17705243
    [Abstract] [Full Text] [Related]

  • 29. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K, Vaculikova M, Dolezel M, Petera J, Moravek P, Prosvic P, Zoul Z, Vosmik M, Dolezal J, Simakova E.
    Oncol Rep; 2005 Oct 01; 14(4):1077-81. PubMed ID: 16142375
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients.
    Nakagami Y, Ohori M, Sakamoto N, Koga S, Hamada R, Hatano T, Tachibana M.
    Int J Urol; 2010 Jul 01; 17(7):629-34. PubMed ID: 20438593
    [Abstract] [Full Text] [Related]

  • 31. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
    Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ.
    Cancer; 2006 Jan 01; 106(1):58-62. PubMed ID: 16329138
    [Abstract] [Full Text] [Related]

  • 32. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, Cancer Leukemia Group B.
    Cancer; 2008 Dec 01; 113(11):3137-45. PubMed ID: 18989865
    [Abstract] [Full Text] [Related]

  • 33. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
    Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K.
    Prostate; 2005 Apr 01; 63(1):1-12. PubMed ID: 15378520
    [Abstract] [Full Text] [Related]

  • 34. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb 01; 15(81):6-7. PubMed ID: 16548096
    [Abstract] [Full Text] [Related]

  • 35. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 01; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 36. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
    Awakura Y, Yamamoto M, Fukuzawa S, Itoh N, Nonomura M, Fukuyama T.
    Hinyokika Kiyo; 2000 Jul 01; 46(7):449-52. PubMed ID: 10965448
    [Abstract] [Full Text] [Related]

  • 37. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I, Destefanis P, Addeo A, Galetto A, Cucchiarale G, Munoz F, Zitella A, Ferrando U, Fontana D, Ricardi U, Tizzani A, Bertetto O.
    Am J Clin Oncol; 2007 Jun 01; 30(3):234-8. PubMed ID: 17551298
    [Abstract] [Full Text] [Related]

  • 38. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
    Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM.
    Cancer; 2006 Jul 15; 107(2):266-74. PubMed ID: 16779800
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK.
    BJU Int; 2005 Oct 15; 96(6):783-6. PubMed ID: 16153200
    [Abstract] [Full Text] [Related]

  • 40. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y, Kikuchi K, Takahashi W, Honda J, Nakanishi J, Matsumoto K, Kuwahara T, Kai N, Kikukawa H, Ueda S.
    Cancer Chemother Pharmacol; 2008 Jan 15; 61(1):53-61. PubMed ID: 17375305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.